CMND Stock Overview
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clearmind Medicine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.18 |
| 52 Week High | US$23.70 |
| 52 Week Low | US$0.92 |
| Beta | -1.69 |
| 1 Month Change | 2.61% |
| 3 Month Change | -31.40% |
| 1 Year Change | -93.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMND | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.5% | 3.0% | -0.7% |
| 1Y | -93.6% | 12.5% | 22.8% |
Return vs Industry: CMND underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: CMND underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| CMND volatility | |
|---|---|
| CMND Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CMND's share price has been volatile over the past 3 months.
Volatility Over Time: CMND's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Adi Zuloff-Shani | www.clearmindmedicine.com |
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.
Clearmind Medicine Inc. Fundamentals Summary
| CMND fundamental statistics | |
|---|---|
| Market cap | US$3.87m |
| Earnings (TTM) | -US$8.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs CMND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMND income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.09m |
| Earnings | -US$8.09m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CMND perform over the long term?
See historical performance and comparison